

# IQUAM Declaration

## Position statement of IQUAM

On 15 July 2006, IQUAM issued its VII<sup>th</sup> position statement, which reads as follows:

IQUAM, the International Committee for Quality Assurance, Medical Technologies and devices in plastic surgery, is a professional medical and scientific organization committed to the surveillance of existing and new medical technologies, devices and procedures in plastic surgery and is dedicated to their safe use and to the guarantee of patients' safety. IQUAM reviews and evaluates updated literature and studies, scientific data and recommends standards of treatment for new devices or technologies. IQUAM proscribes potentially deleterious use of products, devices and technologies or their unintended application or application for unsuitable indications.

### BREAST IMPLANTS

The purpose of breast implant surgery is to improve the mental and physical condition of the patient. The breast implants should be chosen depending on the needs of the patient and their compatibility in the individual case.

#### Silicone gel-filled breast implants

- A. Since IQUAM's former declarations, silicone gel continues to be widely used for breast implants. No better alternative material is available.
- B. Additional medical studies have not demonstrated any association between silicone-gel filled breast implants and cancer or any other disease. These studies re-confirm prior data.<sup>[1-4]</sup>
- C. Silicone-gel filled breast implants do not adversely affect pregnancy, fetal development, breast-feeding or the health of breast-fed children.<sup>[5-8]</sup>
- D. Further changes in implants structure and composition need to be evaluated.

#### Titanium-coated breast implants

Implants made of titanium and titanium alloys are regarded

as inert and they are widely used in implantology. Nonetheless, literature reveals that metallic implants release ions, induce a cytokine cascade that resembles a pro-inflammatory cytokine and subsequently cellular reaction<sup>[9]</sup> and that especially titanium- and titanium alloy particles and debris from fretting and wear are of concern. These particles are being transported to remote sites such as lymph nodes, liver and spleen and even are capable of causing splenomegaly and visceral granulomatosis.<sup>[10,11]</sup> They seem to play a critical role in the phenomenon of "aseptic loosening" of such implants, where polyethylene particles arising from joint cups may add to an unfavourable inflammatory tissue reaction.<sup>[12,13]</sup> To our knowledge, there are and have been breast implants with their silicone envelopes coated with titanium. In regard of the experiences made with hip implants of titanium and titanium alloys, which are per se mechanically heavily loaded and the ongoing debate about debris and particles originating from silicone breast implants and their contribution to capsular contraction, long-term studies and tissue analysis regarding possible particulate debris including remote sites should be presented by manufacturers.

IQUAM calls for clinical and scientific research, for documentation and monitoring of breast implants and similar devices coated with titanium and recommends not using these devices before proper scientific and clinical data are available and to closely monitor patients in whom this type of breast implants were implanted.

#### Hydrogel-filled breast implants

The safety of the hydrogel-filled breast implants has not been established; they have been removed from the market in the U.K.<sup>[14]</sup>

No new data have arisen to support the safety and efficacy of hydrogel-filled implants.<sup>[15-17]</sup>

#### Triglyceride (soybean oil)-filled breast implants (Trilucent™)

- A. Laboratory findings and evaluation of available data,<sup>[18]</sup>

[Addendum I], indicate the presence of potentially hazardous components in the breakdown products of the triglyceride (soybean oil) filler.<sup>[19-22]</sup>

- B. Not all of the triglyceride-filled breast implants have been explanted to date and IQUAM, therefore, emphasizes the need for immediate explantation of the remaining implants.
  - C. Long term follow-up of this group of patients is recommended even after explantation.
- General references <sup>[23-42]</sup>

### **General recommendations for breast augmentation and reconstruction**

- A. IQUAM believes it is important to advise patients of potential hazards and risks, the possible need for re-operations, as well as the benefits of breast augmentation or reconstructive surgery. A detailed and updated Patients Information and Consent Form must be provided and discussed with the patient prior to surgery.
- B. A reasonable period of time should be allotted following consultation, for the comprehension and evaluation of data before decision and performance of surgery.
- C. It is recommended to postpone breast augmentation surgery until after the age of eighteen years, unless medically indicated.
- D. Patients with breast implants should have regular follow-up, preferably by the operating surgeon.<sup>[43-46]</sup>
- E. No definite period of time has yet been defined for the longevity of breast implants. Routine replacement of implants is therefore not mandatory.
- F. IQUAM calls for continuous clinical and scientific research, for documentation and monitoring of breast implants and patients by means of a national and/or international registry.
- G. Advertising of breast implant procedures should be restricted to the medical aspects of the surgery and refrain from presenting it as being risk-free.
- H. IQUAM calls for the approval of silicone-gel filled breast implants for global clinical use and unrestricted availability to all patients.

### **National and the international breast implant registry (IBIR)**

IQUAM first called for the implementation of the international breast implant registry (IBIR) in its Consensus Declaration made in June 1998. The IBIR has been launched and is functioning very well. Statistics of

incidence rates, risk factors and short-term complications are now available.<sup>[47-54]</sup>

Plastic surgeons participating in the breast implant registries commit to high quality medical practice. IBIR activity should be evaluated in the framework of striving for safety and excellence.

IQUAM believes that registries of breast implants are crucial to monitor and document the safety of breast implants. IQUAM appreciates the importance of breast implant registries to ensure women's well being and safety. National Health Authorities and National Societies of Plastic Surgery should encourage plastic surgeons to participate in national registries and/or IBIR.

IBIR enables individual plastic surgeons to submit data directly or through their national societies. It also reassures patients, surgeons, health authorities and the general public of the commitment to safety on the part of the plastic surgery community and for the implementation of medical devices and technologies used in plastic surgery.

Public funds and other sources should be made available to further develop breast implant registries.

IQUAM endorses the IBIR and calls for registries of the national societies to link with IBIR. It is recommended that statistics gathered by national registries should be processed through IBIR.

IQUAM recommends that registration of breast implantations should be obligatory.

### **Tissue engineering**

Tissue engineering is a promising road for future advancements in plastic surgery. Laboratory engineered constructs must consist of safe components before implantation in patients. Institutions such as C. E. N. must set strict measures.

### **Ultrasound-assisted lipoplasty (UAL)**

- A. UAL, VASER and external ultrasound have been used in aesthetic surgery as a substitute for or in conjunction with conventional liposuction. Immediate adverse effects have been reported and evaluated. Long-term biosafety has been questioned in light of the generation of acoustic cavitation with

the consequent production of free radicals, sonoluminescence, high pressures and thermal effects.<sup>[55,56]</sup>

- B. The use of antioxidants in clinical application of the various UAL and VASER techniques may limit associated risks.<sup>[57]</sup>
- C. Further basic science research is mandatory to evaluate risks and to ensure better and safer clinical application.
- D. Safety and efficacy of external (focused) US for aesthetic use has not been established.

## INJECTABLES

### **Lipolysis or lipodissolve injections by phosphatidylcholine derivatives**

Phosphatidylcholine has been used for various clinical indications for many years. Phosphatidylcholine is currently being used 'off label' for dissolving fat in clinical aesthetic applications. Data concerning the outcome and the safety of its use have not yet been established. Further basic science and clinical trials should precede the use of this drug for aesthetic application.<sup>[58-65]</sup>

### **Botulinum toxin A**

- A. Botulinum Toxin A (BTxA) has been extensively used for aesthetic purposes.
- B. BTxA in high dosages has been used in various clinical applications with minimal reported significant adverse effects.
- C. Current clinical data confirm the safety of BTxA's for aesthetic indications when used by experienced doctors under medically acceptable conditions.
- D. Patients should be provided with detailed information and a signed informed consent should be obtained prior to performing the procedure [Addendum III].

### **Injectable fillers**

Various resorbable and non-resorbable injectable materials for soft tissue augmentation are available at present. They include biological and synthetic sources and should be classified as temporary or permanent. 'Semi permanent' fillers, (filler containing temporary and permanent components),<sup>[66]</sup> should be regarded as permanent. The term 'Semi permanent' is confusing and IQAM recommends that it should be abandoned.

Furthermore, IQAM stresses that degradability should be discerned from resorbability.

All permanent implants are associated with risks of infection and granuloma formation, which may lead to major disfigurement. The risks depend on the nature of the implant, volume and depth of injected material, site of injection and multiple other factors. Permanent fillers (excluding autogenous tissue) have been reported to be associated with long-term irreversible complications and should be used with extreme caution.

IQUAM recommends reporting complications and the mandatory registration of adverse effects associated with injections of fillers to regulatory bodies in order to better estimate the extent of complications associated with injectable filling materials. Substantial biochemical and biophysical differences and variations in substance and purity between the commercial products exist. Not all of these have stood the test of time and several should still be considered to be experimental.

The regulation of injectables varies widely from country to country. Approval is often gained after short-term studies of only a few months. To avoid confusion in the use of materials, IQAM recommends that users verify the validation of the CE-mark or FDA approval prior to clinical use.

However, appropriate guidelines are often lacking and as their clinical use expands rapidly, there is considerable overlap in application. More choices demand greater clinical judgement and continuing clinical trials to highlight the differences, the safety, the efficacy and the evolution of the use of these materials.

Numerous case reports describing various complications following the injection of liquid silicone raise concern regarding its use for aesthetic purposes. The main concern regarding silicone injections seems to be its migratory capacity and the generation of early or delayed foreign body reaction.<sup>[67-76]</sup> IQAM's current position is to sustain the ban on the use of liquid silicone in aesthetic plastic surgery.<sup>[77]</sup>

Clinical studies performed by manufacturers are not always sufficient to predict the incidence of late reactions, when a product becomes available for cosmetic purposes.

Continued long-term post-marketing surveillance by both

industry and notified bodies is essential. Physicians should stay alert to detect late adverse events and report these to the competent authorities.

Patients and users need to be given updated information on the risks of these materials.

Supply of injectables should be limited to trained physicians.

Injections of permanent fillers in relatively high volumes, especially hydrogels, have been reported to cause severe irreversible damage and therefore have generated substantial concern. After reviewing the accumulated reports, IQUAM recommends that permanent hydrogels should not be used due to the high incidence of severe complications.<sup>[78-83]</sup>

IQUAM urges governments to pass legislation to protect patients from unduly trained physicians and non-medical personnel injecting materials for various indications.

Based on past experience IQUAM states that CE-marks and FDA approvals are required steps in establishing the safety of medical devices, but are not necessarily sufficient. Post market surveillance revealing new adverse information should lead to reconsideration of the approval status. Therefore, it is the IQUAM's members' imperative duty to continuously monitor the short and long term outcomes to protect the safety of patients.

Objective medical and media reports contribute to the reassurance of patients. IQUAM will continue to provide updated information about medical devices in general, implants in particular, injectables and new technologies in plastic surgery.

Regensburg, Germany, 15<sup>th</sup> July 2006

## REFERENCES

- Bondurant S, Ernster V, Herdman R, editors. Safety of silicone breast implants, Report of the committee on the safety of silicone breast implants, Division of health promotion and disease prevention, Institute of medicine (hereinafter IOM). National Academy Press: Washington, D.C; [cited on 1999 Jun 22]. Available from: [www4.nationalacademies.org/news.nsf](http://www4.nationalacademies.org/news.nsf).
- United Kingdom Report of the Independent Review Group (hereinafter IRG) "Silicone Gel Breast Implants," p25. Available from: [www.silicone-review.gov.uk](http://www.silicone-review.gov.uk).
- European Parliament Directorate General for Research, Scientific and Technological Options Assessment (hereinafter STOA) "Health Risks Posed by Silicone Implants in General with Special Attention to Breast Implants – Final Study". European Parliament Resolution on the petitions declared admissible concerning silicone implants (Petitions Nos 470/1998 and 771/1998) (2001/2068[INI]). p. 22-23. Available from: [www.europarl.eu.int](http://www.europarl.eu.int).
- Health Council of the Netherlands (hereinafter Netherlands) "Gezondheidsrisico's van siliconen- borstimplantaten – Health Risks of Silicone Breast Implants" English Executive Summary. P. 11. Available from: [www.gezondheidsraad.nl](http://www.gezondheidsraad.nl)
- IOM: p. 204.
- IRG: p. 24
- STOA: p. 25-6.
- Netherlands; p. 34.
- Krischka, *et al.* Arch Orth Traum Surg 2004.
- Cunningham, *et al.* Spine 2003.
- Urban *et al.* JBJS 2000.
- Rizzo M, Pace TB. Premature failure of a hip hemiarthroplasty secondary to osteolysis and aseptic loosening. Am J Orthop 2003;32:206-9.
- Fornasier *et al.* J Biomed Mater Res B Appl Biomater 2004.
- Available from: [http://www.mhra.gov.uk/home/idcplg?IdcService=SS\\_GET\\_PAGE&nodoid=738](http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodoid=738).
- Arion H. Carboxymethylcellulose hydrogel-filled breast implants. Our experience in 15 years. Ann Chir Plast Esthet 2002;46:55-9.
- Benediktsson K, Perbeck LG. Fluid retention in Bioplasty Misti Gold II breast prostheses with development of capsular contracture. Scand J Plast Reconstr Surg Hand Surg 2000;34:65-70.
- Ersek RA, Salisbury AV. Textured surface, nonsilicone gel breast implants: Four years' clinical outcome. Plast Reconstr Surg 1997;100:1729-39.
- Topaz M, Oppikofer C, Mokady S, Cogan U. Evidence of Extreme Oxidative State of Soybean Oil-filled (Trilucent™) Breast Implants – Safety Concerns. Abstract of presentation given at the International Symposium of the American Society for Aesthetic Plastic Surgery: Las Vegas; 2002.
- MDA HN 2000(05) Trilucent™ Breast Implants: Recommendation to Remove. Manufacturer/supplier Lipomatrix Inc. / AEI Inc. (formerly Collagen Aesthetics International Inc.) [cited on 2000 Jun]. Available from: <http://www.medical-devices.gov.uk>.
- Assessment of Health Risks Associated with Exposure to Soybean Oil Filler Compounds and Peroxidation Products Potentially Released from Trilucent Breast Implants. Prepared for AEI Inc Gary M. Williams, M.D Professor of Pathology Director, Environmental Pathology and Toxicology. New York Medical College Valhalla: New York; 2000.
- Monstrey S, Delanghe J, Christophe A, Dhooge W, deGreyt W, Bernard D, *et al.* Biocompatibility and oxidative stability of radiolucent breast implants. Plast Reconstr Surg 2000;105:1429-34.
- Papanastasiou S, Odili J, Newman P, Evans J. Are triglyceride breast implants really biocompatible? Ann Plast Surg 2000;45:172-6.
- Gherardini G, Zaccheddu R, Basoccu G. Trilucent breast implants: Voluntary removal following the Medical Device Agency recommendation. Report on 115 consecutive patients. Plast Reconstr Surg 2004;113:1024-7.
- Monstrey S, Christophe A, Delanghe J, De Vriese S, Hamdi M, Van Landuyt K, *et al.* What exactly was wrong with the Trilucent breast implants? A unifying hypothesis. Plast Reconstr Surg 2004;113:847-56.
- Cicchetti S, Spina B, Nicolo G, Santi PL. Trilucent breast implants:

- Five years' experience from an Italian perspective. *Ann Plast Surg* 2003;51:229-35.
26. Pritchard SA, Howe MC, Haboubi NY, Orton CI. Histological appearances of Trilucent breast implant capsules. *Br J Plast Surg* 2003;56:519-20.
  27. Hobman J, Liddington M. Inflammatory expansion of a breast augmented by a Trilucent implant. *Br J Plast Surg* 2002;55:694-5.
  28. Chatrath P, Oliver DW, Walker MS, Lamberty BG. Anti-soya antibodies and trilucent breast implants. *Plast Reconstr Surg* 2003;111:98-102.
  29. Kirkpatrick WN, Jones BM. The history of Trilucent implants and a chemical analysis of the triglyceride filler in 51 consecutively removed Trilucent breast prostheses. *Br J Plast Surg* 2002;55:479-89.
  30. Colville RJ, McLean NR, Cross PA. True double capsules in oil-based (Trilucent) breast implants. *Br J Plast Surg* 2002;55:270-1.
  31. McGregor JC, Brown DT. Observations on a consecutive series of patients who have had Trilucent breast implants removed as recommended by the MDA Hazard Notice (May 2000). *Br J Plast Surg* 2002;55:231-4.
  32. Elson EM, Jones A, King R, Chapman P, Stanek J, Irvine AT, *et al.* Magnetic resonance imaging of Trilucent TM breast implants. *Clin Radiol* 2002;57:263-7.
  33. Rizkalla M, Webb J, Chuo CB, Matthews RN. Experience of explantation of Trilucent breast implants. *Br J Plast Surg* 2002;55:117-9.
  34. Munker R, Zorner C, McKiernan D, Opitz J. Prospective study of clinical findings and changes in 56 Trilucent implant explantations. *Aesthetic Plast Surg* 2001;25:421-6.
  35. McArthur PA, Green AR, Hancock K, Green AR. Histological examination of the capsules surrounding Trilucent breast implants. *Br J Plast Surg* 2001;54:684-6.
  36. McGregor JC. Further comment on Trilucent breast implants. *Br J Plast Surg* 2001;54:466-7.
  37. Ballesta AJ, Delgado DE, Miserachs BN, Ros CV. Rupture of Trilucent-type breast implants: A clinical case. *Aesthetic Plast Surg* 2001;25:43-5.
  38. McGregor JC. Trilucent breast implants: A personal review of the current controversies (May 1999). *Scott Med J* 2000;45:177-9.
  39. Rizkalla M, Duncan C, Matthews RN. Trilucent breast implants: A 3 year series. *Br J Plast Surg* 2001;54:125-7.
  40. Armstrong AP, Jones BM. Patient satisfaction with Trilucent breast implants. *Br J Plast Surg* 2000;53:479-83.
  41. Choudhary S, Cadier MA, Cottrell BJ. Local tissue reactions to oil-based breast implant bleed. *Br J Plast Surg* 2000;53:317-8.
  42. Austin A. Adverse incident reporting to the medical devices agency: A review of reports involving trilucent breast implants. *Br J Plast Surg* 2000;53:313-6.
  43. IOM: p. 215.
  44. IRG: p. 25.
  45. STOA: p. 23.
  46. Netherlands: p. 11.
  47. Available from: [www.ibir.org](http://www.ibir.org).
  48. Henriksen TF, Thuesen B. A nationwide registry for plastic surgery of the breast. *Ugeskr Læger* 2001;163:1692.
  49. Henriksen TF, Olsen JH. The danish registry for plastic surgery of the breast. Status report: 2002.
  50. Henriksen TF, Olsen JH. The Danish Registry for Plastic Surgery of the Breast. Status report: 2003.
  51. Henriksen TF, Hölmich LR, Friis S, McLaughlin JK, Fryzek J, Høyer AP, *et al.* The Danish Registry for Plastic Surgery of the Breast: Establishment of a nationwide registry for prospective follow-up, quality assessment and investigation of breast surgery. *Plast Reconstr Surg* 2003;111:2182-91.
  52. Henriksen TF, Hölmich LR, Fryzek JP, Friis S, McLaughlin JK, Høyer AP, *et al.* Incidence and severity of short-term complications after breast augmentation: Results from a nationwide breast implant registry. *Ann Plast Surg* 2003;51:531-9.
  53. Henriksen TF, Fryzek JP, Hölmich LR, McLaughlin JK, Kjølner K, Høyer AP, *et al.* Surgical intervention and capsular contracture after breast augmentation: A prospective study of risk factors. *Ann Plast Surg* 2005;54:343-51.
  54. Henriksen TF, Fryzek JP, Hölmich LR, McLaughlin JK, Krag C, Karlsen R, *et al.* Reconstructive breast implantation after mastectomy for breast cancer: Clinical outcomes in a nationwide, prospective cohort study. *Arch Surg* 2005;140:1152-9.
  55. Topaz M. Long-Term Possible Hazardous Effects of Ultrasonically Assisted Lipoplasty. Letter to the Editor. *Plast Reconstr Surg* 1998;102:280.
  56. Topaz M, Gedanken A, Koltypin Y, Motiei M. Sonochemistry and Sonoluminescence in Simulated Ultrasound- assisted Lipoplasty Environment. *Aesthetic Surg J* 1999;19:205-13.
  57. Topaz M, Motiei M, Gedanken A, Meyerstein D, Meyerstein N. EPR Analysis of Radicals Generated by High-Intensity Ultrasound Energy in Ultrasound-Assisted Lipoplasty - Simulated Environment. *Ultrasound Med Biol* 2001;27:851-9.
  58. Ablon G, Rotunda Am. Treatment of lower eyelid fat pads using phosphatidylcholine: Clinical trial and review. *Dermatol Surg* 2004;30:422-8.
  59. Bates B. 'Fat dissolving' substance injects CCs of controversy. *Skin Allergy News* 2003;34:1.
  60. Hexsel D, Serra M, Mazzuco R, Dal'Forno T, Zechmeister D. Phosphatidylcholine in the treatment of localized fat. *J Drugs Dermatol* 2003;2:511-8.
  61. Rittes PG. The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads. *Dermatol Surg* 2001;27:391-2.
  62. Rittes PG. The use of phosphatidylcholine for correction of localized fat deposits. *Aesthetic Plast Surg* 2003;27:315-8.
  63. Rittes PG, Rittes JC, Amary MF. Injection of Phosphatidylcholine in Fat Tissue: Experimental Study of Local Action in Rabbits. *Aesthetic Plast Surg* 2006;30:474-8.
  64. Rotunda AM, Kolodney MS. Mesotherapy and phosphatidylcholine injections: Historical clarification and review. *Dermatol Surg* 2006;32:465-80.
  65. Young VL. Lipostabil: The effect of phosphatidylcholine on subcutaneous fat. *Aesth Surg J* 2003;23:413-7.
  66. Bergeret-Galley C, Latouche X, Illouz YG. The value of a new filler material in corrective and cosmetic surgery: DermaLive and DermaDeep. *Aesthetic Plast Surg* 2001;25:249-55.
  67. Achauer BM. A serious complication following medical-grade silicone injection of the face (Case report). *Plast Reconstr Surg* 1983;71:251-4.
  68. Amemiya T, Dake Y. Granuloma after augmentation of the eyelids with liquid silicone: An electron microscopic study. *Ophthal Plast Reconstr Surg* 1994;10:51-6.
  69. Mason J, Apisarnthanarax P. Migratory silicone granuloma. *Arch Dermatol* 1981;117:366-7.
  70. Milojevic B. Complications after silicone injection therapy in aesthetic plastic surgery. *Aesth Pls Surg* 1982;6:203-6.
  71. Parmley VC, Barishak YR, Howes EL, Crawford JB. Foreign-body giant cell reaction to liquid silicone. *Am J Ophthal* 1986;101:680-3.
  72. Raszewski R, Guyuron B, Lash RH, McMahon JT, Tuthill RJ. A

- severe fibrotic reaction after cosmetic liquid silicone injection (Case report). *J Craniomaxfac Surg* 1990;18:225-8.
73. Travis WD, Balogh K, Abraham JL. Silicone granulomas: Report of three cases and review of the literature. *Hum Pathol* 1985;16:19-27.
  74. Wassermann RJ, Greenwald DP. Debilitating silicone granuloma of the penis and scrotum. *Ann Plast Surg* 1995;35:505-10.
  75. Wilkie TF. Late development of granuloma after liquid silicone injections. *Plast Reconstr Surg* 1977;60:179-88.
  76. Zandi I. Use of suction to treat soft tissue injected with liquid silicone. *Plast Reconstr Surg* 1985;76:307-9.
  77. Available from: <http://www.fda.gov/bbs/topics/NEWS/NEW00267.html>
  78. Cheng NX, Wang YL, Wang JH, Zhang XM, Zhong H. Complications of breast augmentation with injected hydrophilic polyacrylamide gel. *Aesthetic Plast Surg* 2002;26:375-82.
  79. Christensen LH, Breiting VB, Aasted A, Jorgensen A, Kebuladze I. Long-term effects of polyacrylamide hydrogel on human breast tissue. *Plast Reconstr Surg* 2003;111:1883-90.
  80. Christensen L, Breiting V. Management of postoperative complications of breast augmentation by injected polyacrylamide hydrogel. Letter to the Editor. *Aesthetic Plast Surg* 2006;30:132.
  81. Evstatiev D. Late complications after application of polyacrylamide hydrogel. *Eur J Plast Surg* 2006;29:127-32.
  82. Niedzielska I, Pajak J, Drugacz J. Late complications after polyacrylamide hydrogel injection into facial soft tissues. Letter to the Editor. *Aesthetic Plast Surg* 2006;30:377-8.
  83. von Buelow S, von Heimburg D, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial and soft-tissue augmentation. *Plast Reconstr Surg* 2005;116:1137-46.